Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06376474
Status:
RECRUITING
Last Update Posted:
2024-06-25
First Post:
2024-04-09
Brief Title:
To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage
Sponsor:
Ganzhou Hemay Pharmaceutical Co Ltd
Organization:
Ganzhou Hemay Pharmaceutical Co Ltd
Study Overview
Official Title:
To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Mild Moderate Liver Impairment and Normal Liver Function After a Single Oral Administration
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study was to evaluate the pharmacokinetics of Hemay 005 tablets in subjects with mild moderate liver impairment and normal liver function and to provide a basis for the formulation of clinical medication regimens for patients with liver impairment
Detailed Description:
To evaluate the pharmacokinetics and safety of Hemay 005 tablets in subjects with mild moderate liver impairment and normal liver function and to provide a basis for the formulation of clinical medication regimens for patients with liver impairment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None